Skip to main content

Organon & Co. (OGN)

NYSE: OGN · IEX Real-Time Price · USD
33.69 0.31 (0.93%)
Sep 24, 2021 4:00 PM EDT - Market closed
Market Cap8.54B
Revenue (ttm)7.89B
Net Income (ttm)n/a
Shares Out253.52M
EPS (ttm)6.86
PE Ratio4.91
Forward PE5.03
Dividend$1.12 (3.32%)
Ex-Dividend DateAug 20, 2021
Volume1,888,126
Open33.50
Previous Close33.38
Day's Range33.00 - 33.95
52-Week Range27.03 - 38.75
Betan/a
AnalystsBuy
Price Target41.80 (+24.1%)
Est. Earnings DateNov 11, 2021

About OGN

Organon & Co., a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio in the United States, Ca...

IndustryDrug Manufacturers-General
Founded1923
Employees9,000
Stock ExchangeNYSE
Ticker SymbolOGN
Full Company Profile

Financial Performance

In 2020, Organon's revenue was $8.10 billion, a decrease of -15.05% compared to the previous year's $9.53 billion. Earnings were $2.16 billion, a decrease of -32.88%.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for Organon stock is "Buy." The 12-month stock price forecast is 41.80, which is an increase of 24.07% from the latest price.

Price Target
$41.80
(24.07% upside)
Analyst Consensus: Buy

News

Organon Aims to Ignite Worldwide Conversation Around Unplanned Pregnancy

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon issues Public Service Announcement inviting women to ignite a global conversation on unplanned pregnancy.

5 days ago - Business Wire

3 Reasons To Buy Organon Stock, Says BofA Analyst

Organon & Co (NYSE:OGN), which has recently spun-off from Merck & Co., Inc. (NYSE:MRK), has “inherited a global business across three segments,” namely Women's Health, Legacy and Biosimilars brands, acc...

3 weeks ago - Benzinga

Organon To Present at Morgan Stanley's 19th Annual Global Healthcare Virtual Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...

3 weeks ago - Business Wire

Organon To Present at Citi's 16th Annual BioPharma Virtual Conference

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), announced today that Kevin Ali, Chief Executive Officer, and Matthew Walsh, Chief Financial Officer, are scheduled to participate in a ...

3 weeks ago - Business Wire

Avestria Ventures Closes Fund I

SAN FRANCISCO--(BUSINESS WIRE)-- #femalefounders--Avestria Ventures closes Fund I. The Bay Area-based venture capital firm invests in women's health and female-led life science ventures.

1 month ago - Business Wire

Jeff Auxier Discloses Position in Organon, Curbs Several Top Holdings

Auxier Asset Management leader Jeff Auxier (Trades, Portfolio) released his second-quarter portfolio last week.

1 month ago - GuruFocus

Top Stocks Warren Buffett Just Bought

These were Berkshire Hathaway's biggest buys during Q2, 2021.

Other symbols:AONKRMRKRH
1 month ago - The Motley Fool

GuruFocus Announces Winner of 2nd-Quarter Warren Buffett Contest

GuruFocus is proud to announce that there was one winner of the second-quarter Warren Buffett (Trades, Portfolio) contest: Steak.

Other symbols:AONKRRH
1 month ago - GuruFocus

Warren Buffett Sells Biotech Holdings After a Year

Yesterday, Warren Buffett (Trades, Portfolio)'s Berkshire Hathaway ( BRK.A , Financial)( BRK.B , Financial) published its 13F report for the period ending June 30.

Other symbols:BIIBBMYGMMRK
1 month ago - GuruFocus

11 Stocks Warren Buffett Is Selling (And 3 He's Buying)

Berkshire Hathaway CEO Warren Buffett and his team were bears yet again in Q2 2021, hacking away at a large number of positions while only adding to a handful.

1 month ago - Kiplinger

Buffett Adds More Kroger, Welcomes Organon in Q2

Berkshire Hathaway's latest 13F filing revealed Warren Buffett sold plenty of stocks in Q2 2021, but added to his Kroger position and gained a "new" stake in Merck spin-off Organon.

Other symbols:KR
1 month ago - Kiplinger

Organon Stock Jumps On Profit Beat In First Post-Spinoff Report

Total revenue of $1.6 billion grew by a modest 4.5% YOY (-1% excluding foreign currency impact or excl.fx) reflecting the impact of loss of exclusivity on some products, but beat consensus by 5.2%.

1 month ago - Forbes

Organon's (OGN) Q2 Earnings & Revenues Surpass Estimates

Organon's (OGN) earnings and revenues beat estimates in the second quarter of 2021. Stock up in pre-market trading.

1 month ago - Zacks Investment Research

Organon Reports Results for the Second Quarter Ended June 30, 2021 and Announces Inaugural Dividend

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN) (the “company”), today announced its results for the second quarter and year to date ended June 30, 2021 and affirmed its full year 2021...

1 month ago - Business Wire

5 Undervalued Stocks Popular Among Gurus

GuruFocus' Most Broadly Held model portfolio consists of the 25 stocks that have the highest number of guru owners, rebalanced annually.

Other symbols:BABABIDUCMRK
1 month ago - GuruFocus

Organon and ObsEva Enter Global License Agreement to Develop and Commercialize Ebopiprant (OBE022), an Investigationa...

JERSEY CITY, N.J. & GENEVA, Switzerland--(BUSINESS WIRE)-- #Health--Organon (NYSE: OGN), a global women's health company and ObsEva (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company dedicated to i...

Other symbols:OBSV
1 month ago - Business Wire

Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon To Report Fiscal Q2 Results and Host Conference Call on August 12, 2021

2 months ago - Business Wire

3 Stocks I'd Avoid at All Costs

On the surface, these companies seem like underpriced investments, but look a little closer and there's a good reason to stay away.

Other symbols:PPLRIDE
2 months ago - The Motley Fool

Should Investors Hold Out Hope for bluebird bio and Merck Spinoff Organon?

Neither healthcare stock has performed well so far this year.

Other symbols:BLUEMRK
2 months ago - The Motley Fool

Stay Away From Low-Growth Organon

Organon's low growth, lack of strong catalysts and likely average future dividend combine to make OGN stock unattractive. The post Stay Away From Low-Growth Organon appeared first on InvestorPlace.

2 months ago - InvestorPlace

Spinoffs Roundup: These Companies Could Unlock Value in 2021

Some spinoffs can unlock the true value of businesses by allowing them to focus on their niches better than being part of a bulkier multi-faceted corporation allows. On the other hand, some spinoffs are...

Other symbols:CGNTVMEO
2 months ago - GuruFocus

Why Merck's Organon Spinoff Could Be Worth Billions

Don't think of Merck spinoff Organon as a research engine. The new pharmaceutical stock is a pure-play commercial entity.

2 months ago - Investors Business Daily

Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Recommends Stockholders Reject Below-Market Mini-Tender Offer by TRC Capital Investment Corporation

2 months ago - Business Wire

Don't Miss the Opportunity Presented by Organon Stock

If a company's spun off from a pharmaceutical giant, you'd think the buzz about it would be deafening. Yet OGN stock remains an underappreciated gem.

3 months ago - InvestorPlace

Organon Announces Filing of Form 10-Q for the Quarter Ended March 31, 2021

JERSEY CITY, N.J.--(BUSINESS WIRE)-- #Health--Organon Announces Filing of Form 10-Q for the quarter ended March 31, 2021

3 months ago - Business Wire